Page 7 - Nasdaq Prtk News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek’s Management Team...

Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) and IMV (NASDAQ:IMV – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. Analyst Ratings This is a breakdown of current ratings and […]

Analysts expect that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) will announce ($0.35) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Paratek Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.34). Paratek Pharmaceuticals reported earnings […]

Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) and Kintara Therapeutics (NASDAQ:KTRA – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Profitability This table compares Paratek Pharmaceuticals and Kintara Therapeutics’ […]

Equities research analysts expect that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) will report sales of $27.15 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Paratek Pharmaceuticals’ earnings. The highest sales estimate is $27.30 million and the lowest is $27.00 million. Paratek Pharmaceuticals posted sales of $16.43 million […]